stockportfolio.pro
Stocks / ENSG vs RGC
ENSG vs RGC
The Ensign Group, Inc. and Regencell Bioscience Holdings Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
RGC is the larger company ($9.3B vs $8.9B). On the fundamentals, ENSG has the stronger return on equity (15.4% vs -52.3%). Full numbers below — the stronger figure on each row is in green.
| The Ensign Group, Inc. (ENSG) | Regencell Bioscience Holdings Limited (RGC) | |
|---|---|---|
| Market cap | $8.9B | $9.3B |
| Revenue (latest FY) | $5.06B | $0 |
| Net income (latest FY) | $343.97M | $-4.30M |
| Revenue growth (5y CAGR) | 16.1% | — |
| Net margin | 6.8% | — |
| Return on equity | 15.4% | -52.3% |
| P/E ratio | 24.6 | — |
| Dividend yield | 0.2% | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | — | No |
Compare with another company:
See the full ENSG vs RGC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ENSG's full financials → Open RGC's full financials →More comparisons
Frequently asked questions
Which is bigger, ENSG or RGC?
Regencell Bioscience Holdings Limited is larger by market capitalization — $9.3B versus $8.9B.
Which grows faster, ENSG or RGC?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.